Background and Objectives The impact on long-term adverse cardiac events of troponin T TnT or creatine kinase-MB CK-MB release after percutaneous transluminal coronary angioplasty PTCA is not well defined. The purpose of the study is to evaluate the effect of elevated TnT or CK-MB on the late major adverse cardiac events [MACE Q wave myocardial infarction MI , revascularization, or cardiac death]. Subjects and Methods Study population were 207 consecutive patients M F 148 59, mean 60.8 9.2 years who underwent PTCA. Patients with acute MI, unstable angina with abnormal levels of TnT or CK-MB, or newly developed Q MI after PTCA were excluded. Cardiac enzyme levels were measured before and 8, 24 hours after PTCA for CK-MB, and before and 16 hours after PTCA for TnT. Group I n 181, 87.4% had normal levels of both after PTCA. Group II n 26, 12.6% had abnormal levels of CK-MB 16 U/L and/or TnT 0.2 ng/mL . 1-year follow-up was available in 201 97.1% patients. Results Incidence of non-Q MI after PTCA was 26/207 12.6% . Major complications such as acute coronary occlusion, side branch occlusion, and major dissection were significantly associated with elevation of TnT or CK-MB after PTCA p 0.01 . However, elevation of CK-MB or TnT was not significantly associated with late MACE by Kaplan-Meier survival curve p 0.46 . During 1-year follow-up, event free rate of group I and II were 76.6% and 69.2%, respectively. Conclusion Acute coronary occlusion, side branch occlusion, or major dissection can increase the level of TnT or CK-MB after PTCA. But, elevation of CK-MB or TnT after PTCA dose not

